Bevacizumab In Advanced Angiosarcoma: What Is The Reality?

previous preclinical and clinical evidence regarding the use of antiangiogenic therapy in angiosarcoma. Before incorporating these results into clinical practice, it would be prudent to review a few facts. First, although the incidence of angiosarcoma is relatively rare, the sample size of the study was small and, thus, undermines the statistical ability to draw any strong clinical conclusion. Second, a concomitantbiomarker study(eg, plasma level of VEGF, sVEGFR-2, etc) could provide some insight into the antiangiogenic activity in angiosarcoma (preintervention and postintervention change in serum levels of the aforementioned biomarkers), similar to the recent study of sorafenib in pediatric solid tumors. 5 Third, a recent study showed overexpression of the phosphatidylinositol 3-kinase/ Akt/mammalian target of rapamycin pathway in angiosarcoma, 6